Prof. Zelber-Sagi is a clinical dietitian, epidemiologist and a researcher in nutritional epidemiology. She holds a BSc in nutrition sciences at the Hebrew University and a PhD in epidemiology and preventive medicine at the Sackler School of Medicine at Tel Aviv University. Currently, Prof Zelber-Sagi is the Head of School of Public Health, University of Haifa. She also works as a clinical dietitian at the liver Unit of the Tel-Aviv hospital. She is a member of the “National Committee for Nutrition, Gastroenterology and Liver Disease” and Head of the “Gastroenterology and Hepatology Nutrition forum” on behalf of The Israeli Nutrition Association. She is also a member of UEG’s Public Affairs Committee and former member of the EASL’s Policy and Public Health Committee. Her research deals mainly with non-alcoholic fatty liver disease (NAFLD) epidemiology, prevention and treatment.

Sirpa Pietikäinen is a Finnish politician and Member of the European Parliament (MEP) from Finland. She is a member of the National Coalition Party, part of the European People's Party. She has been a Member of the European Parliament (MEP) since 2008, and was re-elected in 2009 and 2014. She is member of the MEP Friends of the Liver group. Pietikäinen has an MBA degree from Helsinki School of Economics. She has received The Knight Commander's Order of the White Rose of Finland (1993).

Mojca Matičič, EASL Policy and Public Health Committee Member (2018-2022), is Head of the Viral Hepatitis Unit and Head of the STI Outpatient Service at the Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre in Ljubljana, Slovenia. She is also a Full Professor of Infectious Diseases and Epidemiology at the Faculty of Medicine, University of Ljubljana. After gaining her medical degree, Professor Matičič specialised in internal medicine and in infectious diseases at the University of Ljubljana, before completing a masters and PhD in HIV/AIDS and HCV, respectively. Subsequently, she undertook international postdoctoral training at the Middlesex Hospital and Royal Free Hospital in London, UK. Professor Matičič’s research interests focus on viral infections, primarily viral hepatitis, antiviral treatment and STIs. An active member of numerous professional societies including EASL (European association for the Study of the Liver), where she is a member of the Policy and Public Health Committee (PPHC), Hepatitis B&C Public Policy Association (HepB&C PPA), ESCMID (European Society of Clinical Microbiology and Infectious Diseases), and INHSU (International Network for management of Hepatitis in Substance Users), she currently leads a hepatitis C study group at C-EHRN (Correlation-European Harm Reduction Network), serves as an advisor to WHO (World Health Organization) Europe, ECDC (European Center for Disease Control) and the VHPB (Viral Hepatitis Prevention Board). Professor Matičič is also a member of the HIV/AIDS Committee of the Slovene Ministry of Health and a co-author of the National Strategy for the Management of HCV Infection in Slovenia (1997). She leads the Slovene National Viral Hepatitis Expert Board and co-authored the national clinical practice guidelines for the treatment of HCV and HBV infections. She has authored or co-authored more than 450 articles in national and international peer-reviewed journals, EASL Policy and Position statements and organised numerous national and international conferences.

Sara Cerdas is a Portuguese medical doctor and since July of 2019 a Member of European Parliament. She is member on the Committee on the Environment, Public Health and Food Safety and substitute member on the Committee on Transport and Tourism. She is also member of the special committee on beating cancer and the S&D shadow rapporteur for the EU4Health Programme. Sara Cerdas is co-chair in the European Parliament's Working Group on Health, which brings to discussion European health issues with stakeholders and experts. She holds a master's degree in Medicine from the University of Lisbon, a master's degree in Public Health from the University of Umeå and is a doctoral student in Public Health Sciences from the University of Stockholm. During her career, she had work in the Epidemiology Department of Portuguese Health National Institute and in The Public Health Emergency Centre of the Portuguese Directorate-General of Health, having an active participation in tackling regional and national outbreaks.

Maria Buti is currently Professor of Medicine and consultant of Hepatology at the Hospital General Universitari Valle Hebron, Barcelona and the EASL Public Health Councillor. Dr Buti has worked in viral hepatitis for the last 35 years, particularly in diagnosis and therapy of hepatitis B , C and D. She has published more than 500 papers the field of liver disease, with numerous papers and contributions to books.

Dr Norah Terrault is the Chief of Gastroenterology & Hepatology at Keck Medical Center of USC and the President of the American Association for the Study of Liver Diseases (AASLD). She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines.

Dr Mario Pessoa is an Assistant-Professor at Division of Gastroenterology and Hepatology at University of São Paulo School of Medicine - HCFMUSP. He coordinates the Medical Residency of Clinical Gastroenterology and Hepatology. Dr Pessoa equally works as an Associate Editor of Liver International and Current Hepatitis Reports. He is the Vice President at the Latin American Association for the Study of the Liver (ALEH) and a member of the Brazilian Society of Hepatology as well as the Paulista Association of the Study of the Liver.

Professor Manal El Sayed is Professor of Pediatrics at Ain Shams University and the Co-Chair of the Society on Liver Disease Africa (SOLDA). She is the clinical director of the national HCV Pediatric treatment program and the director of the clinical research unit and co-supervisor of the viral hepatitis treatment center at Ain Shams University. Manal is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) charged with planning and implementing the nationwide program for prevention and management of viral hepatitis since 2006. Manal is also an active board member and secretary general of the Egyptian Liver Care Society.

Marko Korenjak is the President of European Liver Patients Association (ELPA) and president of Slovenian Association for patients with viral hepatitis - Slovenija HEP. He is a member of EASL, International Communication Association (ICA), and International NLP Trainer Association (INLPTA). In 2014 he wrote a book about his fight against hepatitis C with the title, 336 Days of Hope. In 2017 he was selected by Economist Intelligence Unit as one of 18 most influential individuals and/or organisations in the fight against hepatitis C.

Patrizia Burra is Associate Professor of Gastroenterology and Head of Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology at the Padua University Hospital, Italy. Patrizia Burra is internationally recognized as an expert in hepatology and liver transplantation. She is the current Public Affairs Group Chair at United European Gastroenterology (UEG) and the Past President of the International Liver Transplant Society (ILTS). She has authored more than 280 articles in international peer-reviewed journals, with an H-index of 46.

Donna R. Cryer, JD, she is the founder and CEO of Global Liver Institute (GLI). She received a life-saving liver transplant in law school after years of living with an autoimmune disease. On the 20th anniversary of her transplant, she realized her experience as a patient, lawyer, and professional health systems consultant could help fellow patients. In 2014, she founded Global Liver Institute. She is widely recognized as an expert on the topics of patient engagement in research, digital health, and high-value equitable care.

Prof. Loreta Kondili is a specialist in Gastroenterology and Digestive Endoscopy since 2005 and earned her Ph.D. degree in 2015. She is trained in Sapienza University and Policlinico Umberto 1- Rome and in the Liver Unit of Queen Elisabeth Hospital/ University of Birmingham (UK). She is a Clinical Researcher at the Center for Global Health, Istituto Superiore di Sanità, Rome. Prof. Kondili has worked in viral hepatitis and liver diseases for the last 25 years, and her main research areas focus on epidemiological, clinical, and therapy of chronic viral liver disease. She has been involved in the scientific coordination of several Italian Networks in the field of chronic liver disease of different etiologies with specific regard to chronic viral hepatitis, liver cirrhosis, and its complications. She is currently the principal investigator of the Italian Platform for the study of Viral Hepatitis Therapies (PITER). She has strong competencies in the Health Technology Assessment and management and analysis of real-life big databases. She has collaborated with the Center for Economic and International Studies (CEIS) of the Tor Vergata University of Rome and the Center for Disease Analysis Colorado (USA), for the definition of the HCV elimination strategies in Italy as a goal of the World Health Organization. She is currently serving as expert for the Italian Ministry of Health on the implementation of the National Hepatitis plan. She has been an expert of the Italian Drug Agency (AIFA) and is currently serving as expert at European Medicines Agency (EMA) She is a Professor of Medicine at the University of Tirana. She passed the National Scientific Qualification as Associated Professor (Bando D.D. 1532/2016 Settore concorsuale 06/D4 Fascia: II). She holds a 2nd level master’s in Evaluation and Management of Health Technologies from the Catholic University of Rome. She is a member of the Italian Association for the Study of the Liver and of the European Association for the Study of the Liver (EASL) serving also as a member of the Policy and Public Health Committee of EASL. Prof Kondili has co-authored over 100 publications on hepatitis and is a frequent speaker in national and international scientific meetings.

Sonjelle Shilton joined the Foundation for Innovative New Diagnostics (FIND) in January 2017 and is currently Deputy Director, Operational Implementation Research, Foundation for Innovative New Diagnostics (FIND). Sonjelle started her career in public health as Director of Operations of HardtHaven, a community-based health outreach organization in rural Ghana. She has over fifteen years of experience in leading programmes and implementation science studies. Her time in Ghana cemented her dedication to public health approaches that are collaboratively designed and implemented with rigorous and meaningful data capture. She attained a Master of Global Public Health and the Global WACh Graduate Certificate for integrated health of Women, Adolescents and Children from the University of Washington, USA.

Maurizia R. Brunetto is Director of the Integrated Care Department of Medical Specialties and of the Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital.  Her research activity has been focused on the study of the pathogenetic implications of hepatitis virus infection, on the analysis of factors influencing the progression of chronic hepatitis to cirrhosis and hepatocellular carcinoma and on the treatment optimization. She did seminal work in the clinic-pathologic characterization of the HBeAg negative chronic hepatitis B with the identification of Pre-core mutant and demonstrated  the clinical usefulness of HBsAg serum levels measurement in the monitoring of antiviral      therapy and identification of HBeAg negative infection with the definition of the clinical cut-off, currently suggested by the international guidelines.

Lindsey Hiebert is the Associate Director of the Coalition for Global Hepatitis Elimination. The Coalition is based at the Task Force for Global Health, an international NGO in Atlanta, United States. At the Coalition, Lindsey supports initiatives related to technical assistance, operational research, advocacy, and policy to advance hepatitis B and C elimination globally.

Dr Jess Dyson is a consultant hepatologist at the Freeman Hospital in Newcastle with a combined role as an NHS hepatologist with a major interest in clinical research based at Newcastle University. She leads the clinical service in Newcastle for patients with autoimmune liver disease including running the regional network for delivery of 2nd-line therapies in high risk primary biliary cholangitis. She is principal investigator for the UK national study for patients with autoimmune hepatitis that focuses on improving therapy for patients (UK-AIH) and a co-author on the national guidelines for primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis. She completed her PhD in 2019 investigating potential environmental risk factors related to autoimmune liver disease.

Robert Mitchell-Thain is Chief Executive Officer at the PBC Foundation and Chair of Paediatric and Rare Liver Diseases Council at the Global Liver Institute. Mitchell-Thain is a fierce patient advocate with over 20 years of international experience. A NAFLD patient himself, his main focus has been cholestatic liver disease. A member of numerous collaborative committees, lead and co-author on several patient-centric abstracts, co-author and reviewer of clinical guidelines and journal articles, he is known for challenging dogma and for a progressive approach to finding solutions in a patient-centred way, pursuing the best for all stakeholders within the community.

Jeffrey V. Lazarus (Ph.D., MIH, MA) is a Member of the EASL Policy and Public Health Committee. He holds positions as an associate research professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, where he leads the health systems research team, as Associate Professor at the Faculty of Medicine, University of Barcelona, Spain and as a senior scholar at the CUNY Graduate School of Public Health and Policy in New York City. His decade-long career as health systems, HIV, and viral hepatitis expert at WHO Europe was followed by three years (2009-2012) as a senior specialist at the Global Fund to Fight AIDS, Tuberculosis, and Malaria, three years as director of Health Systems Global (2012-15) then board chair of the foundation AFEW International (2015-18). Prof Lazarus is now Vice-Chairman of the board of the EASL International Liver Foundation, where he developed the micro-elimination approach to HCV elimination. He is also a member of the INHSU international education committee and co-chair of the HIV Outcomes Beyond Viral Suppression coalition. He is the author of more than 300 publications and his current scientific work includes leading the Hep C Free Baleares, HBV COMSAVA, and Copenhagen T'n'T studies, and the Global COVID-19 consensus statement on ending the pandemic. He is a core member of The Lancet GastroHep Commission on Viral Hepatitis, a co-author of the Lancet COVID-19 commission and a commissioner of the EASL-Lancet European Liver Commission and The Lancet-IAPAC HIV Commission. At AME/VE he is chair of the NAFLD models of care workshop, on the organizing committee of COLDA, and on the scientific committee of IVHEM.

Prof. Maja Thiele works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research centers on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection, cost-effective referral pathways and omics technologies. Elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, AASLD clinical guidance, WFUMB guideline, and The Lancet Commission on liver disease in primary care. Partner in the European research consortia GALAXY, LiverScreen, LIVERAIM, MicrobPredict and SALVE.

Josep M. Llovet, MD, PhD is Professor of Medicine – Hepatic Oncology at University of Barcelona, Group leader and Professor of Research-ICREA in the Liver Unit, IDIBAPS-Hospital Clinic and Director of the Liver Cancer Program and Professor of Medicine at the Icahn School of Medicine at Mount Sinai, NY. He has devoted his career to the pathogenesis and treatment of liver cancer, publishing ~ 350 articles (~ 136,049 citations, h index: 134) and leading ~100 projects. He has been nominated as global Top-1% cited researcher (2014 to 2022) and nominated Editor in Chief of JHEP Reports (2024-29).

Richard Price is Head of Policy at European Cancer Organisation (ECO). He is a public policy professional with extensive experience in the healthcare and pharmaceutical sectors working as a policy manager in EU Affairs at ECO, policy and advocacy officer at the European Association of Hospital Pharmacists, and as policy advisor to the Pharmaceutical Society of Northern Ireland.

Nick Sheron is an academic clinical hepatologist at University of Southampton and runs the liver unit at Southampton General Hospital. He is also actively involved in a clinically based programme of research in various aspects of alcohol-related problems. Together with Ian Gilmore, President of the Royal College of Physicians, he co-founded the Alcohol Health Alliance UK, an umbrella body bring together 27 different organisations including Royal Colleges, NGOs and charities with the aim of lobbying for evidence-based policies to reduce alcohol-related harm in the UK. He is also a founder member of the European Union Alcohol Forum, a member of the European Union Alcohol Marketing Taskforce and two bodies of which have been set up by the European Commission in order to take forward the EU Alcohol Strategy.

Florence Berteletti has over 20 years of international policy and advocacy experience in diverse fields including fiscal policies for health, tobacco control, alcohol related harm and culture policy. Florence Berteletti was appointed Secretary General of Eurocare in August 2021. Between 2018 and August 2021, Florence was Advocacy Director at the World Heart Federation where she was responsible for leading WHF’s global policy and advocacy and led dossiers related to Front of Pack Labelling, Fiscal Policies for Health, Rheumatic Heart Diseases and Air pollution, to name just a few. Before WHF, Florence was Director of the Smoke Free Partnership (SFP), an alliance of 52 civil society organisations dedicated to the implementation of the WH Framework Convention on Tobacco Control (FCTC).